OVID Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 8.06%, SMA50 2.94%, SMA200 46.69%). The stock’s 14-day RSI is 56.14 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.91% below its high and over 580.41% above its low. Average 10-day trading volume of 1.36 million shares is below the 3-month average of 3.08 million, indicating normal recent market interest.

Ovid Therapeutics Inc. has 71.11 million shares outstanding. The public float is 59.52 million shares, elevated short interest at 2.70% of float. This equals 1.61 million shares. The short ratio is 0.69 days. Institutional investors hold 41.45% of the float. Insiders own 16.31%. TAKEDA PHARMACEUTICAL CO LTD holds 5.75 million shares, Rakhit Amit has 726.82 thousand shares and Rona Jeffrey A has 88.19 thousand shares. Over the past six months, insider transactions show net selling. They sold 20.20 thousand shares across 2 transactions.

Ovid Therapeutics Inc. generated EPS of -$0.51 over the past year. Five-year average earnings growth is 24.72%. Wall Street analysts project EPS growth of -13.2% annually over the next five years. The latest quarter delivered EPS of $0.06. The next quarter is forecast at -$0.12. Next year's EPS is expected at $14.01. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $2.00. The high target offers 152.71% upside. The low target suggests -27.8% downside. The mean target is $4.22. This offers 52.35% upside. Ovid Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended March 18, 2026, missed forecasts by -160.0%. The prior quarter beat by 89.98%. Over the last six quarters, Apple has recorded several small beats. These include 5.26% in November 12, 2024.

Ovid Therapeutics Inc. (NASDAQ:OVID) closed at $2.96 USD, gaining $0.17 (6.09%) from the previous close of $2.79. The stock is currently within 5% of its 52-week high $0.27 and $3.10. With a market capitalization of about $390.38 million, Ovid Therapeutics Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.03). Key stats such as the average daily volume over the past year has been around 3.03 million shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Ovid Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Margaret Alexander, the company employs approximately 23 people and listed since May 05, 2017. Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.

Ovid Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.15. This means the shares are trading below this model’s fair value.

Ovid Therapeutics Inc. trades at a P/E ratio of -13.09, slightly below the S&P 500 average, with a price-to-sales ratio of 50.74 and a price-to-book ratio of 1.74 suggesting the stock is closer to book value. The P/FCF stands at -9.6, also below market averages.

Ovid Therapeutics Inc. (NASDAQ:OVID) shares are flat -6.75% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ovid Therapeutics Inc. trading at a premium to the broader market with a P/E of -13.09. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $5.79, suggesting 109.03% upside. Our AI forecast model points to short-term strength (7.94% over two weeks), a medium-term rise (34.3% over three months), and a longer-term gain (887.73% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Ovid Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.94%, with price expected at $2.99 by May 14, 2026, within a range of $2.78 to $3.23 3-Month Outlook: Projected rise of 34.3%, reaching $3.72 by July 29, 2026, with a range of $3.66 to $3.77. 1-Year Outlook: Projected gain of 887.73%, with price at $27.36 by April 30, 2027, within a range of $28.24 to $34.37.